- Home
- API vs NMRA Comparison
API vs NMRA Comparison
Compare API & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- NMRA
- Stock Information
- Founded
- API 2013
- NMRA 2019
- Country
- API United States
- NMRA United States
- Employees
- API N/A
- NMRA N/A
- Industry
- API Computer Software: Prepackaged Software
- NMRA
- Sector
- API Technology
- NMRA
- Exchange
- API Nasdaq
- NMRA Nasdaq
- Market Cap
- API 283.7M
- NMRA 287.6M
- IPO Year
- API 2020
- NMRA 2023
- Fundamental
- Price
- API $3.37
- NMRA $0.66
- Analyst Decision
- API Strong Buy
- NMRA Buy
- Analyst Count
- API 1
- NMRA 8
- Target Price
- API $6.00
- NMRA $9.29
- AVG Volume (30 Days)
- API 820.8K
- NMRA 891.0K
- Earning Date
- API 05-27-2025
- NMRA 05-12-2025
- Dividend Yield
- API N/A
- NMRA N/A
- EPS Growth
- API N/A
- NMRA N/A
- EPS
- API N/A
- NMRA N/A
- Revenue
- API $133,256,000.00
- NMRA N/A
- Revenue This Year
- API $6.89
- NMRA N/A
- Revenue Next Year
- API $10.96
- NMRA N/A
- P/E Ratio
- API N/A
- NMRA N/A
- Revenue Growth
- API N/A
- NMRA N/A
- 52 Week Low
- API $1.65
- NMRA $0.62
- 52 Week High
- API $6.99
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- API 47.08
- NMRA 31.99
- Support Level
- API $3.24
- NMRA $0.63
- Resistance Level
- API $3.53
- NMRA $0.72
- Average True Range (ATR)
- API 0.20
- NMRA 0.06
- MACD
- API 0.11
- NMRA 0.02
- Stochastic Oscillator
- API 77.45
- NMRA 18.80
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.